Loading…

Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18 F-FDG PET Scans for Suspected Cardiac Sarcoidosis

This study sought to evaluate the incremental value of quantifying the extent and severity of myocardial perfusion and F-labeled fluorodeoxyglucose (FDG) abnormalities in predicting adverse outcomes among patients with suspicion for cardiac sarcoidosis (CS). Positron emission tomography (PET) with F...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Cardiovascular imaging 2018-02, Vol.11 (2 Pt 2), p.336
Main Authors: Sperry, Brett W, Tamarappoo, Balaji K, Oldan, Jorge D, Javed, Omair, Culver, Daniel A, Brunken, Richard, Cerqueira, Manuel D, Hachamovitch, Rory
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 2 Pt 2
container_start_page 336
container_title JACC. Cardiovascular imaging
container_volume 11
creator Sperry, Brett W
Tamarappoo, Balaji K
Oldan, Jorge D
Javed, Omair
Culver, Daniel A
Brunken, Richard
Cerqueira, Manuel D
Hachamovitch, Rory
description This study sought to evaluate the incremental value of quantifying the extent and severity of myocardial perfusion and F-labeled fluorodeoxyglucose (FDG) abnormalities in predicting adverse outcomes among patients with suspicion for cardiac sarcoidosis (CS). Positron emission tomography (PET) with FDG is a key component of the noninvasive assessment of patients with suspected CS. However, the optimal method for image interpretation has not been defined. A retrospective analysis was performed of 203 patients who underwent perfusion and FDG-PET imaging to evaluate for CS. Imaging findings were scored by conventional 3-category methods (normal perfusion and metabolism, abnormal perfusion or metabolism, abnormal perfusion and metabolism) and by summed scores using the 17-segment model to represent extent and severity of disease. Heterogeneity of metabolism was quantified using the coefficient of variation (SD divided by the mean) of FDG uptake. Multivariable Cox models were developed to assess associations between imaging findings and adverse events (death, heart transplant, or ventricular arrhythmia requiring defibrillation). The indication for FDG-PET was ventricular arrhythmia in 69 (34%), heart block in 16 (8%), cardiomyopathy in 54 (27%), and other indications in 64 (32%). There were 63 patients who developed adverse events over a mean follow-up of 1.8 years. After robust adjustment, only the summed score in segments with a perfusion-metabolism mismatch and the coefficient of variation were important prognostically (p = 0.029 and p = 0.041, respectively). Quantitative measures of extent and severity of perfusion-metabolism mismatch and coefficient of variation of FDG uptake provide an incremental prognostic advantage in patients undergoing FDG-PET for CS. These results support the use of a more detailed analysis of imaging findings, as is conventional in coronary artery disease.
doi_str_mv 10.1016/j.jcmg.2017.04.020
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_28823747</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28823747</sourcerecordid><originalsourceid>FETCH-pubmed_primary_288237473</originalsourceid><addsrcrecordid>eNqFzr1uwjAYhWGrUlXozw10QN8FENcOaRzGChJgQwo7MvYX5AjbkW2qMnLnpVI7dzrSq2c4hLxyRjnj5VtPe2WPNGdcUFZQlrM7MuaVKDPxPucj8hhjz1jJykI8kFFeVflMFGJMrtvgj87HZBRs7CBVAt9B_ZXQpSm0-InBpMsUpNOwxoQ3jQ5v6Yd9HJwPVp5MMhjBO-AVNFmzXMG23kGrpIvQ-QDtOQ6oEmpYyKCNVNDKoLzRPpr4TO47eYr48rtPZNLUu8U6G84Hi3o_BGNluOz_Ps_-Bd_BGVLi</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18 F-FDG PET Scans for Suspected Cardiac Sarcoidosis</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><creator>Sperry, Brett W ; Tamarappoo, Balaji K ; Oldan, Jorge D ; Javed, Omair ; Culver, Daniel A ; Brunken, Richard ; Cerqueira, Manuel D ; Hachamovitch, Rory</creator><creatorcontrib>Sperry, Brett W ; Tamarappoo, Balaji K ; Oldan, Jorge D ; Javed, Omair ; Culver, Daniel A ; Brunken, Richard ; Cerqueira, Manuel D ; Hachamovitch, Rory</creatorcontrib><description>This study sought to evaluate the incremental value of quantifying the extent and severity of myocardial perfusion and F-labeled fluorodeoxyglucose (FDG) abnormalities in predicting adverse outcomes among patients with suspicion for cardiac sarcoidosis (CS). Positron emission tomography (PET) with FDG is a key component of the noninvasive assessment of patients with suspected CS. However, the optimal method for image interpretation has not been defined. A retrospective analysis was performed of 203 patients who underwent perfusion and FDG-PET imaging to evaluate for CS. Imaging findings were scored by conventional 3-category methods (normal perfusion and metabolism, abnormal perfusion or metabolism, abnormal perfusion and metabolism) and by summed scores using the 17-segment model to represent extent and severity of disease. Heterogeneity of metabolism was quantified using the coefficient of variation (SD divided by the mean) of FDG uptake. Multivariable Cox models were developed to assess associations between imaging findings and adverse events (death, heart transplant, or ventricular arrhythmia requiring defibrillation). The indication for FDG-PET was ventricular arrhythmia in 69 (34%), heart block in 16 (8%), cardiomyopathy in 54 (27%), and other indications in 64 (32%). There were 63 patients who developed adverse events over a mean follow-up of 1.8 years. After robust adjustment, only the summed score in segments with a perfusion-metabolism mismatch and the coefficient of variation were important prognostically (p = 0.029 and p = 0.041, respectively). Quantitative measures of extent and severity of perfusion-metabolism mismatch and coefficient of variation of FDG uptake provide an incremental prognostic advantage in patients undergoing FDG-PET for CS. These results support the use of a more detailed analysis of imaging findings, as is conventional in coronary artery disease.</description><identifier>EISSN: 1876-7591</identifier><identifier>DOI: 10.1016/j.jcmg.2017.04.020</identifier><identifier>PMID: 28823747</identifier><language>eng</language><publisher>United States</publisher><ispartof>JACC. Cardiovascular imaging, 2018-02, Vol.11 (2 Pt 2), p.336</ispartof><rights>Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28823747$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sperry, Brett W</creatorcontrib><creatorcontrib>Tamarappoo, Balaji K</creatorcontrib><creatorcontrib>Oldan, Jorge D</creatorcontrib><creatorcontrib>Javed, Omair</creatorcontrib><creatorcontrib>Culver, Daniel A</creatorcontrib><creatorcontrib>Brunken, Richard</creatorcontrib><creatorcontrib>Cerqueira, Manuel D</creatorcontrib><creatorcontrib>Hachamovitch, Rory</creatorcontrib><title>Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18 F-FDG PET Scans for Suspected Cardiac Sarcoidosis</title><title>JACC. Cardiovascular imaging</title><addtitle>JACC Cardiovasc Imaging</addtitle><description>This study sought to evaluate the incremental value of quantifying the extent and severity of myocardial perfusion and F-labeled fluorodeoxyglucose (FDG) abnormalities in predicting adverse outcomes among patients with suspicion for cardiac sarcoidosis (CS). Positron emission tomography (PET) with FDG is a key component of the noninvasive assessment of patients with suspected CS. However, the optimal method for image interpretation has not been defined. A retrospective analysis was performed of 203 patients who underwent perfusion and FDG-PET imaging to evaluate for CS. Imaging findings were scored by conventional 3-category methods (normal perfusion and metabolism, abnormal perfusion or metabolism, abnormal perfusion and metabolism) and by summed scores using the 17-segment model to represent extent and severity of disease. Heterogeneity of metabolism was quantified using the coefficient of variation (SD divided by the mean) of FDG uptake. Multivariable Cox models were developed to assess associations between imaging findings and adverse events (death, heart transplant, or ventricular arrhythmia requiring defibrillation). The indication for FDG-PET was ventricular arrhythmia in 69 (34%), heart block in 16 (8%), cardiomyopathy in 54 (27%), and other indications in 64 (32%). There were 63 patients who developed adverse events over a mean follow-up of 1.8 years. After robust adjustment, only the summed score in segments with a perfusion-metabolism mismatch and the coefficient of variation were important prognostically (p = 0.029 and p = 0.041, respectively). Quantitative measures of extent and severity of perfusion-metabolism mismatch and coefficient of variation of FDG uptake provide an incremental prognostic advantage in patients undergoing FDG-PET for CS. These results support the use of a more detailed analysis of imaging findings, as is conventional in coronary artery disease.</description><issn>1876-7591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFzr1uwjAYhWGrUlXozw10QN8FENcOaRzGChJgQwo7MvYX5AjbkW2qMnLnpVI7dzrSq2c4hLxyRjnj5VtPe2WPNGdcUFZQlrM7MuaVKDPxPucj8hhjz1jJykI8kFFeVflMFGJMrtvgj87HZBRs7CBVAt9B_ZXQpSm0-InBpMsUpNOwxoQ3jQ5v6Yd9HJwPVp5MMhjBO-AVNFmzXMG23kGrpIvQ-QDtOQ6oEmpYyKCNVNDKoLzRPpr4TO47eYr48rtPZNLUu8U6G84Hi3o_BGNluOz_Ps_-Bd_BGVLi</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Sperry, Brett W</creator><creator>Tamarappoo, Balaji K</creator><creator>Oldan, Jorge D</creator><creator>Javed, Omair</creator><creator>Culver, Daniel A</creator><creator>Brunken, Richard</creator><creator>Cerqueira, Manuel D</creator><creator>Hachamovitch, Rory</creator><scope>NPM</scope></search><sort><creationdate>201802</creationdate><title>Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18 F-FDG PET Scans for Suspected Cardiac Sarcoidosis</title><author>Sperry, Brett W ; Tamarappoo, Balaji K ; Oldan, Jorge D ; Javed, Omair ; Culver, Daniel A ; Brunken, Richard ; Cerqueira, Manuel D ; Hachamovitch, Rory</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_288237473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sperry, Brett W</creatorcontrib><creatorcontrib>Tamarappoo, Balaji K</creatorcontrib><creatorcontrib>Oldan, Jorge D</creatorcontrib><creatorcontrib>Javed, Omair</creatorcontrib><creatorcontrib>Culver, Daniel A</creatorcontrib><creatorcontrib>Brunken, Richard</creatorcontrib><creatorcontrib>Cerqueira, Manuel D</creatorcontrib><creatorcontrib>Hachamovitch, Rory</creatorcontrib><collection>PubMed</collection><jtitle>JACC. Cardiovascular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sperry, Brett W</au><au>Tamarappoo, Balaji K</au><au>Oldan, Jorge D</au><au>Javed, Omair</au><au>Culver, Daniel A</au><au>Brunken, Richard</au><au>Cerqueira, Manuel D</au><au>Hachamovitch, Rory</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18 F-FDG PET Scans for Suspected Cardiac Sarcoidosis</atitle><jtitle>JACC. Cardiovascular imaging</jtitle><addtitle>JACC Cardiovasc Imaging</addtitle><date>2018-02</date><risdate>2018</risdate><volume>11</volume><issue>2 Pt 2</issue><spage>336</spage><pages>336-</pages><eissn>1876-7591</eissn><abstract>This study sought to evaluate the incremental value of quantifying the extent and severity of myocardial perfusion and F-labeled fluorodeoxyglucose (FDG) abnormalities in predicting adverse outcomes among patients with suspicion for cardiac sarcoidosis (CS). Positron emission tomography (PET) with FDG is a key component of the noninvasive assessment of patients with suspected CS. However, the optimal method for image interpretation has not been defined. A retrospective analysis was performed of 203 patients who underwent perfusion and FDG-PET imaging to evaluate for CS. Imaging findings were scored by conventional 3-category methods (normal perfusion and metabolism, abnormal perfusion or metabolism, abnormal perfusion and metabolism) and by summed scores using the 17-segment model to represent extent and severity of disease. Heterogeneity of metabolism was quantified using the coefficient of variation (SD divided by the mean) of FDG uptake. Multivariable Cox models were developed to assess associations between imaging findings and adverse events (death, heart transplant, or ventricular arrhythmia requiring defibrillation). The indication for FDG-PET was ventricular arrhythmia in 69 (34%), heart block in 16 (8%), cardiomyopathy in 54 (27%), and other indications in 64 (32%). There were 63 patients who developed adverse events over a mean follow-up of 1.8 years. After robust adjustment, only the summed score in segments with a perfusion-metabolism mismatch and the coefficient of variation were important prognostically (p = 0.029 and p = 0.041, respectively). Quantitative measures of extent and severity of perfusion-metabolism mismatch and coefficient of variation of FDG uptake provide an incremental prognostic advantage in patients undergoing FDG-PET for CS. These results support the use of a more detailed analysis of imaging findings, as is conventional in coronary artery disease.</abstract><cop>United States</cop><pmid>28823747</pmid><doi>10.1016/j.jcmg.2017.04.020</doi></addata></record>
fulltext fulltext
identifier EISSN: 1876-7591
ispartof JACC. Cardiovascular imaging, 2018-02, Vol.11 (2 Pt 2), p.336
issn 1876-7591
language eng
recordid cdi_pubmed_primary_28823747
source BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS
title Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18 F-FDG PET Scans for Suspected Cardiac Sarcoidosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T10%3A45%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Impact%20of%20Extent,%20Severity,%20and%20Heterogeneity%20of%20Abnormalities%20on%2018%20F-FDG%20PET%20Scans%20for%20Suspected%20Cardiac%20Sarcoidosis&rft.jtitle=JACC.%20Cardiovascular%20imaging&rft.au=Sperry,%20Brett%20W&rft.date=2018-02&rft.volume=11&rft.issue=2%20Pt%202&rft.spage=336&rft.pages=336-&rft.eissn=1876-7591&rft_id=info:doi/10.1016/j.jcmg.2017.04.020&rft_dat=%3Cpubmed%3E28823747%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-pubmed_primary_288237473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/28823747&rfr_iscdi=true